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Abstract
Background: With the widespread use of anti-retroviral therapy (ART), individuals infected with human immune deficiency
virus (HIV) are increasingly experiencing morbidity and mortality from respiratory disorders. However, the prevalence or the
risk factors associated with emphysema and bronchiolitis are largely unknown.
Methods: Thoracic computed tomography (CT) scans were performed in 1,446 patients infected with HIV who were on ART
and who attended a tertiary care metabolic clinic (average age 48 years and 29% females). Detailed history and physical
examination including anthropometric measurements were performed. Complete pulmonary function tests were
performed in a subset of these patients (n = 364). No subjects were acutely ill with a respiratory condition at the time of
CT scanning.
Findings: Nearly 50% of the subjects had CT evidence for emphysema, bronchiolitis or both with 13% (n = 195) showing
bronchiolitis, 19% (n = 274) showing emphysema and 16% (n = 238) revealing both. These phenotypes were synergistically
associated with reduced regular physical activity (p for interaction ,.0001). The most significant risk factors for both
phenotypes were cigarette smoking, intravenous drug use and peripheral leucocytosis. Together, the area-under-the curve
statistics was 0.713 (p = 0.0037) for discriminating those with and without these phenotypes. There were no significant
changes in lung volumes or flow rates related to these phenotypes, though the carbon monoxide diffusion capacity was
reduced for the emphysema phenotype.
Interpretation: Emphysema and bronchiolitis are extremely common in HIV-infected patients who are treated with ART and
can be identified by use of thoracic CT scanning.
Citation: Guaraldi G, Besutti G, Scaglioni R, Santoro A, Zona S, et al. (2014) The Burden of Image Based Emphysema and Bronchiolitis in HIV-Infected Individuals
on Antiretroviral Therapy. PLoS ONE 9(10): e109027. doi:10.1371/journal.pone.0109027
Editor: Richard van Zyl-Smit, University of Cape Town Lung Institute, South Africa
Received April 24, 2014; Accepted August 14, 2014; Published October 29, 2014
Copyright:  2014 Guaraldi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. Data are available from
the University of Modena (Comitato Etico Provinciale) Ethics Committee for researchers who meet the criteria for access to confidential data.
Funding: The authors have no support or funding to report.
Competing Interests: The authors confirm that co-author Leonardo Fabbri is a PLOS ONE Editorial Board member. However, this does not alter the authors’
adherence to PLOS ONE Editorial policies and criteria.
* Email: pman@providencehealth.bc.ca
Introduction
The widespread use of highly active anti-retroviral therapy
(ART) has dramatically increased the longevity of patients infected
with the human immune deficiency virus (HIV), with mortality
rates falling from 30 at its peak to only 1–3 per 100 person-years.
[1,2] Many individuals with HIV infection in Western Countries
are now living into their 60’s. [3] This improved survival has been
driven largely by a marked reduction in deaths from acquired
immune deficiency syndrome (AIDS)-defining conditions such as
opportunistic infections and AIDS-related malignancies. [4]
However, the impact of ART on non-AIDS defining illnesses
has been less impressive. Currently, these conditions account for
50% to 60% of all deaths. [5] Interestingly, most of these non-
AIDS defining conditions are senescence-related and in HIV
appear to occur two to three decades earlier than those observed
in the non-HIV infected populations. [6,7] While the effects of
HIV on two of the leading non-AIDS defining causes of mortality,
cardiovascular disease and solid organ malignancies, have been
carefully described and studied, [6–9] the relation of HIV with
chronic obstructive pulmonary disease (COPD), another common
senescence-related condition, remains poorly understood. Previous
epidemiological studies suggest that the risk of COPD is
accelerated in individuals with HIV. However, these studies have
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been relatively small in size and scope or failed to properly
phenotype these patients. [10–12] The principal aim of the present
study was to use thoracic computed tomography (CT) imaging to
determine the prevalence of bronchiolitis and emphysema, which
is one of the major morphologic phenotypes of COPD and to
describe risk factors associated with these CT phenotypes in a
large group of HIV infected individuals who were well treated with
ART.
Methods
Cohort Description
This is a prospective observational study of all individuals
infected with HIV who attended an outpatient HIV metabolic
clinic at University of Modena and Reggio Emilia, Italy between
January 2006 and September 2012 and who underwent CT
scanning for cardiac risk assessment. No subject had a clinical
diagnosis of COPD, bronchiectasis or any other chronic respira-
tory condition at the time of evaluation. The project received
approval from the regional institutional ethics review committee at
University of Modena (Comitato Etico Provinciale) and all subjects
provided a written consent to participate in the study. Demo-
graphic data, clinical history, anthropometric assessment, blood
tests, and pulmonary function tests (for those who were enrolled in
2012) were obtained in these subjects. Inclusion criteria were:
serologically documented HIV-1 infection, age more than 18
years, and at least 18 months of ART exposure. Demographic and
clinical data included at the time of CT scanning were: age, sex,
current smoking status and intensity of smoking (i.e., the number
of cigarettes consumed per day for current smokers), previous use
of (illicit) intravenous drugs, a prior history of pneumonia (of any
kind), and a history of pneumocystis jiroveci pneumonia (PJP).
Moreover, through an in-person interview, we ascertained the
subject’s cumulative exposure to major antiretroviral drug classes,
including protease inhibitors (PI) and nucleoside reverse transcrip-
tase inhibitors (NRTI), and their physical activity was determined
on the basis of whether or not the respondents performed 2 or
more hours of exercise per week, which is the minimal level of
exercise recommended for achieving health benefits. [13]
Anthropometric data included: body mass index (BMI), visceral
abdominal adipose tissue volume (VAT) and subcutaneous adipose
tissue (SAT), which were obtained using a single-slice abdominal
CT scan at the level of the L4 vertebra as per standard protocol.
[14] Pulmonary function testing was conducted using Jaeger Flow
Screen spirometer and a Jaeger Master Screen plethysmography
(RA.Med srl Medical technology) according to the ATS/ERS
recommendations. [15].
Thoracic CT Scans
All patients underwent CT imaging with a volume CT 64-slice
scanner (GE Medical Systems, Milwaukee, Wisconsin, USA). All
images were obtained during a single breath hold using 320 mAs
and 140 kV. A section thickness of 2.5 mm, a field of view of
20 cm, and a matrix of 5126512 were used to reconstruct the raw
image data, yielding a nominal pixel size of 0.39 mm2 and a voxel
of 0.4 mm3. Until January 2012, images were reconstructed with a
section thickness of 2.5 mm and a display field of view of 20 cm.
Image acquisition commenced above the bronchial carina to the
cardiac apex. From February 2012 and through completion of
enrollment in September 2012, Z axis coverage was extended from
the lung apices to the lung bases with reconstruction with a wide
display field of view (FOV) of 40 cm.
Images were reviewed by 3 radiologists by consensus reading
using an offline CT workstation (AW 4.4, GE Healthcare,
Milwaukee, WI). Images were evaluated for findings of emphy-
sema, and bronchiolitis as defined by the Fleischner Society
glossary of terms. [13] We did not include ‘‘tree in bud’’ nodularity
in the definition of bronchiolitis to reduce the likelihood of
inclusion of infectious causes of bronchiolitis. Based on a modified
method of Kazerooni et al, [16] semi-quantitative scores were
assigned to all scans. A score (between 0 to 4) was assigned to each
of 6 lobes (for a maximum score of 24) to describe the burden of
lung emphysema manifested as bullae, centrilobular or paraseptal
lesions. A total score of 0 indicated the absence of emphysema; a
score of 1–2 indicated a mild degree of emphysema; 3–4 denoted a
moderate amount of emphysema; and .4 indicated severe
emphysema. Bronchial abnormalities were detected by noting
bronchiolitis, manifesting as centrilobular nodules or tree in bud.
Respiratory bronchiolitis, when present, was semi-quantitatively
graded into 4 categories: 0 to 4 according to the amount of
centrilobular micronodules and patchy ground-glass opacity, with
or without fine fibrosis.
Laboratory Studies
Blood was collected using standard venipuncture methods after
an overnight fast. CD4 T-lymphocyte count, nadir CD4 T-cell
count, quantitative plasma HIV-1 RNA (Real Time Abbott
Molecular Inc., Des Plaines, IL, USA), C-reactive protein (CRP)
was measured in the blood samples using standard assays with
1.1 mg/L as the lower limit of detection. These measurements
were performed at the metabolic clinic, the University of Modena
and Reggio Emilia, Italy. Pulmonary function tests were
performed according to ATS/ERS standards with the subjects
seated. [17] Inhaled salbutamol (400 ug) was provided when
subjects demonstrated airflow limitation as defined by forced
expiratory volume in one second (FEV1) to forced vital capacity
(FVC) was less than 70%. Thus, FEV1 and FVC used in this study
represent post-bronchodilator values for those who demonstrated
airflow limitation and pre-bronchodilator values when they did
not. Diffusing capacity of the lung for carbon monoxide (DLCO)
was measured using the single breath method in accordance with
the ATS/ERS recommendations. [18] DLCO values were not
corrected for hemoglobin or carboxyhemoglobin. For normative
values, we used Qunajer’s equation for FEV1 and FVC [19],
Coats’ equation for DLCO [20], and Stocks’ equation for the other
lung volumes [21]. Subjects who were experiencing acute
respiratory illness were excluded from these tests.
Statistical analysis
The cohort was first divided into 4 groups based on the CT
findings: ‘‘no lung disease’’, ‘‘emphysema’’, ‘‘bronchiolitis’’ and
‘‘emphysema plus bronchiolitis’’. The emphysema group con-
tained CT scans that had an emphysema score 1 or greater, while
the bronchiolitis group contained scans with a bronchiolitis score
of 2 or greater. Continuous variables were compared across these
groups using a one-way ANOVA with Bonferroni post hoc testing
for pairwise comparisons. Dichotomous variables were compared
across the groups using a chi-square test or a Fisher’s exact test
(where appropriate) with appropriate degrees of freedom. For
analytic purposes, emphysema was classified into no (score of 0),
mild (1–2), moderate (3–4), and severe (.4) groups and
bronchiolitis was divided into no or trivial (scores of 0 or 1), mild
(2), moderate (3) and severe (4+) groups. A dose relationship was
determined for each of the clinical variables across the emphysema
or bronchiolitis severity gradient using the Mantel-Haenszel test
for trend. To adjust for confounding, we employed multivariate
regression modeling. To create the most parsimonious, yet
statistically robust model, we used Akaike’s Information Criteria
HIV and COPD
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(AIC) for variable selection. The variables that yielded the smallest
AIC values were included in the final model. To determine the
possible clinical utility of knowing these risk factors in discrimi-
nating those with CT changes from those without, we constructed
an area under the curve-receiver operating characteristics (AUC-
ROC) analysis. The variable with the highest AUC-ROC in the
univariate model was chosen as ‘‘model 1’’ (base model). To this
base model, the variable with the second highest AUC-ROC was
added, creating ‘‘model 2’’. To model 2, the variable with the 3rd
highest AUC-ROC was added, creating ‘‘model 3’’. This process
continued until all variables were exhausted or until the
incremental p-value was no longer significant for 2 successive
models. P values less than 0.05 (corrected for multiple compar-
isons) were considered significant and all analyses were conducted
with SAS version 9.3 (Carey, N.C.).
Results
Overall Clinical Characteristics
There were 1,460 patients subjects who underwent 2,037 CT
scans during the study period. We excluded duplicate scans, and
14 technically unsuitable scans (owing to motion artifact) for
analysis, leaving 1,446 subjects (n = 417; 28.8% females) who had
had at least one CT scan that was suitable for analysis (see
Figure 1 for flow diagram). Of these, 258 subjects underwent full
lung scans and 1,188 had cardiac CT scans. All patients were
receiving ART at the time of assessment. The mean age of the
subjects was 48.467.6 years and the mean body mass index (BMI)
was 23.763.8 kg/m2. HIV was well controlled at the time of
assessment with 94% (n= 1,356) of the subjects having an
undetectable plasma viral load. Their mean CD4 count was
6126279 cells/mm3. The average duration of HIV infection,
which was calculated by taking the difference between the date of
study entry and date of HIV diagnosis, was 202675 months.
Approximately 40% (n= 558) of the subjects were current smokers
and 28% (n= 403) had a significant history of previous intravenous
drug use; none were active users at the time of CT assessment. CT
scans demonstrated evidence for bronchiolitis, emphysema or both
in 49% of the subjects (n = 707): 13% (n= 195) showed
bronchiolitis, 19% (n= 274) demonstrated emphysema and 16%
(n= 238) revealed both. The prevalence of emphysema (as defined
by presence of qualitative emphysema score of 1 or greater) was
41% (n= 105) in those who had a full lung scan versus 34%
(n= 406) in those who had a cardiac scan (p= 0.0470). Clinical
characteristics stratified according to CT changes are summarized
in Table 1. Representative images of a subject with emphysema, a
subject with bronchiolitis and a subject without these CT changes
are shown in Figure 2.
There were commonly shared risk factors for both bronchiolitis
and emphysema. These included cigarette smoking, intravenous
drug use, duration of HIV infection, reduced BMI or SAT, a prior
history of pneumonia, and elevated peripheral leukocyte count or
CRP levels (see Tables 2 and 3). There were some notable
discordances in risk factors between the two CT phenotypes. For
instance, increasing age and male sex were significantly related to
emphysema but not to bronchiolitis. Similarly, prior history of PJP
infection was a risk factor for emphysema but not for bronchiolitis.
Conversely, reduced visceral adiposity was a risk factor for
bronchiolitis but not for emphysema. Importantly, both emphy-
sema and bronchiolitis severity scores were associated with
reduced regular physical activity, indicating functional impairment
(see Tables 2 and 3).
Figure 1. Flow Diagram of Patient Selection.
doi:10.1371/journal.pone.0109027.g001
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Relative Importance of Risk Factors
With both CT phenotypes, cigarette smoking was the single
most important risk factor (see Tables S1 and S2). However,
cigarette smoking was associated with a higher r2 value for
bronchiolitis compared with emphysema (0.152 versus 0.063),
suggesting a more prominent role of cigarette smoking in the
Table 1. Clinical Characteristics of the 1,446 Consecutive Subjects With HIV Infection According to COPD Changes on CT Scans.
Group No lung disease Bronchiolitis Emphysema Emphysema + Bronchiolitis Global p value
No of Patients 739 (51%) 195 (13%) 274 (19%) 238 (16%) –
Women 251 (34%) 72 (37%) 46 (17%) 48 (20%) ,.0001
Age (years) 47.467.8 47.166.2 51.267.8* 49.467.1*{ ,.0001
Current Smokers 176 (24%) 110 (58%)* 95 (35%)*` 177 (77%)*{` ,.0001
.10 cigs/day 76 (10%) 61 (31%)` 57 (21%)` 131 (55%)` ,.0001
Intravenous Drug Use 137 (19%) 63 (32%)* 98 (36%)* 105 (44%)* ,.0001
HIV exposure (months) 192676 212676* 211668* 217674* ,.0001
Suppressed viral load 691 (94%) 179 (92%) 260 (95%) 226 (95%) 0.4650
Nadir CD4 (cells/mm3) 2066152 2036176 1756151* 1876181 0.0309
Current CD4 (cells/mm3) 6036258 6336286 5856285 6586323{ 0.0180
Current Use of PI 433 (59%) 151 (55%) 121 (62%) 143 (61%) 0.4962
Current Use of NNRTI 271 (37%) 102 (37%) 62 (32%) 80 (34%) 0.5123
Current Use of NRTI 621 (84%) 244 (89%) 165 (85%) 196 (82%) 0.1384
Body mass index (kg/m2) 24.163.9 23.063.4* 23.863.7 22.863.3*{ ,.0001
Subcutaneous Adipose Tissue
(cm2)
167699 140684* 142689* 125679* ,.0001
Visceral Adipose Tissue (cm2) 132675 115658* 147692*` 125670{ ,.0001
Prior PJP infection 46 (7%) 9 (5%) 28 (12%) 21 (10%) 0.0743
Prior TB infection 11 (1%) 4 (2%) 8 (3%) 7 (3%) 0.3648
Prior Pneumonia 54 (8%) 25 (15%)* 41 (17%)* 39 (18%)* 0.0001
History of Asthma 5 (1%) 6 (4%) 1 (0%) 3 (1%) 0.0241
CRP (.1.1 mg/L) 322 (46%) 87 (48%) 120 (47%) 130 (59%)*` 0.0138
White blood cell (cells/mL) 587261687 609561902 630261931* 749862420*{` ,.0001
Regular Physical activity{{ 350 (49%) 72 (38%)* 115 (43%) 89 (39%)* 0.0088
Dichotomous data are presented as number of individuals (% column totals) and continuous variables are presented as mean6SD.
*p,.05 vs no lung disease, following Bonferroni correction.
`p,.05 vs bronchiolitis, following Bonferroni correction.
{p,.05 vs emphysema, following Bonferroni correction.
{{2 or more hours of physical activity per week.
Abbreviations: cigs, cigarettes; CRP, C-reactive protein; HIV, human immune deficiency; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse
transcriptase inhibitors; PJP, pneumocystis jiroveci pneumonia; PI, protease inhibitors; TB, tuberculosis.
doi:10.1371/journal.pone.0109027.t001
Figure 2. A Representative Image of a Subject with Emphysema (A), a Subject with Bronchiolits (B), and a Subject with both
Emphysema and Bronchiolitis (C). A) A transverse axial image of a 48 year old HIV-infected male, displaying changes of severe emphysema as
manifested by large bullae, as well as paraseptal and centrilobular regions of low attenuation. B) An axial image reconstructed with a small field of
view in a 42 year old HIV-infected female, demonstrating changes of moderate respiratory bronchiolitis with multiple centrilobular nodules scattered
throughout both lungs. C) A transverse axial image of a 44 year old HIV-infected male shows changes of both moderate emphysema and
bronchiolitis.
doi:10.1371/journal.pone.0109027.g002
HIV and COPD
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bronchiolitis phenotype. Peripheral leukocytosis was also strongly
related to both of these phenotypes and accounted for approxi-
mately 5% and 6% of the variances in the bronchiolitis and
emphysema scores, respectively, and intravenous drug use
accounted for 3% of the variance in the bronchiolitis and 4% of
the variance in the emphysema scores (see tables S1 and S2).
Increasing age and sex (each) accounted for 3% of the emphysema
score variance but neither contributed significantly to the
bronchiolitis score. The other risk factors contributed very little
to the overall variance in the CT phenotype scores.
CT Phenotypes and Physiology and Health Outcomes
Lung function measurements were performed in 364 subjects.
Of these, 9.6% demonstrated spirometric evidence for COPD with
51% having GOLD grade 1, 40% having GOLD grade 2 and 9%
GOLD grade 3 disease. Interestingly, 37% of the subjects had
reduced diffusing capacity of the lung for carbon monoxide (DLCO)
defined as DLCO less than 80% of predicted value. The
emphysema phenotype independent of bronchiolits (see Table 2)
or emphysema plus bronchiolitis phenotype (see Table 4) was
associated with impaired gas exchanged. With increasing severity
of emphysema, there was also a progressive reduction in the
FEV1/FVC ratio (see Table 2). However, even in the group with
very severe emphysema (score of .4), the vast majority of subjects
had an FEV1/FVC ratio within normal limits (.0.7). Neither the
bronchiolitis nor emphysema phenotype was associated with
impaired flow rates or representative lung volumes (Table 4).
However, despite the absence of significant physiological pertur-
bations, both emphysema and bronchiolitis was associated with
impairments in physical activity (see Tables 2 and 3). There was a
synergistic interaction of emphysema with bronchiolitis scores on
the risk of impaired physical activity (p for interaction, ,.0001; see
Figure 3). Compared with those without any emphysema or
bronchiolitis, those with severe emphysema (.4) and moderate to
severe bronchiolitis (3+) had a nearly 9 fold increase in the odds of
impaired physical activity (adjusted odds ratio, OR, 8.82; 95% CI,
2.02 to 38.6; p = 0.0408).
Predictors of CT Phenotypes
To determine which risk factors could predict the occurrence of
bronchiolitis or emphysema on thoracic CT scans, we calculated
AUC-ROC values for a select number of clinical and demograph-
ic variables (see Table 5). Smoking alone had an AUC-ROC value
of 0.656 (95% CI, 0.631 to 0.680). Adding peripheral leukocyte
count to the smoking variable increased the AUC-ROC to 0.689
(p = 0.0004). Inclusion of a history of intravenous drug use to
smoking and peripheral leukocyte count increased the AUC-ROC
to 0.713 (p = 0.0037). Addition of age to this model further
increased the AUC-ROC value to 0.730 (p = 0.0360). Although
both BMI and sex were significantly related to CT phenotypes,
their addition did not significantly improve the discriminatory
properties of the model (see Table 5).
Discussion
To our knowledge, this is the largest epidemiological study using
CT scanning to describe the prevalence of emphysema and
bronchiolitis and their risk factors in HIV infected individuals
treated with ARTs. Although the individuals were not selected on
Table 2. Clinical Risk Factors and Health Outcomes for Emphysema.
Emphysema Score (severity) 0 (none) 1–2 (mild) 3–4 (moderate) .4 (severe) P value for trend
No of Patients 935 (65%) 189 (13%) 130 (9%) 192 (13%) –
Women 323 (35%) 34 (18%) 35 (27%) 25 (13%) ,.0001
Age (years) 47.467.5 50.168.1 49.567.4 51.067.1 ,.0001
Current Smokers 286 (31%) 77 (42%) 76 (60) 119 (63%) ,.0001
Intravenous Drug Use 200 (21%) 65 (34%) 49 (38%) 89 (46%) ,.0001
HIV exposure (months) 196675 200678 210671 231673 ,.0001
Nadir CD4 Count (cells/mm3) 2066157 1726144 1866187 1866169 0.0190
Current CD4 Count (cells/mm3) 6096264 5976299 6056320 6526302 0.1518
Body mass index (kg/m2) 23.963.8 24.063.5 23.163.9 22.863.3 0.0002
Subcutaneous Adipose Tissue (cm2) 162697 145687 133684 124683 ,.0001
Visceral Adipose Tissue (cm2) 129672 137686 137686 135679 0.1315
Prior PJP infection 55 (7%) 16 (9%) 16 (14%) 17 (10%) 0.0289
Prior Pneumonia 79 (10%) 27 (16%) 20 (17%) 33 (19%) ,0.001
CRP (.1.1 mg/L) 409 (46%) 87 (49%) 66 (54%) 97 (55%) 0.0120
WBC (/mL) 591561732 639461819 683462320 729562495 ,0.001
FEV1 (% predicted) 105616 109615 100619 104622 0.5937
FEV1/FVC (%) 79.866.5 80.865.9 77.566.9 76.267.3 0.0011
DLCO (% predicted) 77.3615.9 76.2618.1 72.8614.2 65.2612.3 ,.0001
Bronchiolitis Score 0.8060.81 1.2260.96 1.660.95 1.460.96 ,.0001
Regular Physical activity* 423 (47%) 82 (45%) 56 (44%) 65 (35%) 0.0060
Dichotomous data are presented as number of individuals (% column totals) and continuous variables are presented as mean6SD.
*2 or more hours of physical activity per week.
Abbreviations: CRP, C-reactive protein; DLCO, diffusing capacity of lung for carbon monoxide or transfer factor; FEV1, forced expiratory volume in one second; FVC,
forced vital capacity; HIV, human immune deficiency; PJP, pneumocystis jiroveci pneumonia.
doi:10.1371/journal.pone.0109027.t002
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the basis of pulmonary risk factors or symptoms, strikingly, nearly
50% of these patients whose mean age was only 48 years had
imaging evidence for bronchiolitis, emphysema or both and those
who had these CT phenotypes reported reduced physical activity,
suggesting exercise impairment. The single most important risk
factor for the presence of bronchiolitis or emphysema was cigarette
smoking. Additional (independent) risk factors included peripheral
leukocytosis, and a history of intravenous drug use. Together,
these data suggest a complex interplay of environmental irritant
exposure with persistent systemic inflammation that may enhance
and accelerate lung injury, leading to bronchiolitis and emphyse-
ma HIV infected individuals who are on ART.
Why these CT phenotypes develop in relatively young HIV
individuals is not known with any certainty. One suggested
Table 3. Clinical Risk Factors and Health Outcomes for Bronchiolitis.
Bronchiolitis Score (severity) 0–1 (none or trivial) 2 (mild) 3 (moderate) 4+ (severe) P value for trend
No of Patients 1,013 (70%) 362 (25%) 58 (4%) 13 (1%) –
Women 297 (29%) 104 (29%) 12 (21%) 4 (31%) 0.3817
Age (years) 48.468.0 48.567.0 47.065.8 48.466.6 0.5201
Current Smokers 271 (27%) 225 (64%) 50 (89) 12 (92%) ,.0001
Intravenous Drug Use 235 (23%) 130 (36%) 30 (52%) 8 (62%) ,.0001
HIV exposure (months) 197676 210671 236671 230663 ,.0001
Nadir CD4 Count (cells/mm3) 1986152 2006182 1646167 1796111 0.3589
Current CD4 Count (cells/mm3) 5986265 6546310 6226298 5486243 0.0438
Body mass index (kg/m2) 24.163.9 23.163.3 22.163.2 22.063.5 ,.0001
Subcutaneous Adipose Tissue (cm2) 161697 135682 118683 98672 ,.0001
Visceral Adipose Tissue (cm2) 136680 122665 113667 106652 0.0003
Prior PJP infection 74 (8%) 20 (6%) 8 (15%) 2 (15%) 0.0823
Prior Pneumonia 95 (11%) 57 (18%) 7 (13%) 0 (0%) 0.0074
CRP (.1.1 mg/L) 442 (47%) 178 (53%) 30 (56%) 9 (75%) 0.0443
WBC (/mL) 599261768 672362293 766062269 750962433 ,.0001
FEV1 (% predicted) 104.7616.3 106.2618.3 104.7620.1 96.2616.1 0.8522
FEV1/FVC (%) 79.166.9 79.466.3 78.667.4 75.867.4 0.8539
DLCO (% predicted) 76.0616.5 73.3616.0 67.9611.4 71.2613.3 0.0475
Emphysema Score 0.5260.97 1.0561.20 1.5561.17 1.8560.97 ,.0001
Regular physical activity* 465 (47%) 149 (43%) 11 (20%) 1 (8%) ,.0001
Dichotomous data are presented as number of individuals (% column totals) and continuous variables are presented as mean6SD for normally distributed variables or
median (interquartile range) for non-normally distributed variables.
*2 or more hours of physical activity per week.
Abbreviations: CRP, C-reactive protein; DLCO, diffusing capacity of lung for carbon monoxide or transfer factor; FEV1, forced expiratory volume in one second; FVC,
forced vital capacity; HIV, human immune deficiency; PJP, pneumocystis jiroveci pneumonia.
doi:10.1371/journal.pone.0109027.t003
Table 4. Pulmonary Function Test Results Of 364 HIV Infected Subjects Stratified According To CT Based Emphysema Severity.
Emphysema Score (severity) 0 (none) 1–2 (mild) 3–4 (moderate) .4 (severe) P value for trend
No of Patients 207 58 34 65 –
FEV1 (% predicted) 106617 106.8617 104611 101621 0.0438
FVC (% predicted) 109.8637.5 107.1614.5 108.069.7 109.5617.8 0.8561
FEV1/FVC (%) 80.266.6 80.466.0 78.764.3 73.867.7 ,.0001
RV (% predicted) 137.0621.3 142.6618.0 147.9629.1* 146.2625.2 0.0007
TLC (% predicted) 114.2613.5 112.7611.8 113.7611.7 121.1613.2 0.0180
RV/TLC (%) 40.668.0 39.066.2 39.964.3 42.468.2 0.3505
DLCO (% predicted) 78.5613.0 78.7615.6 72.7615.3 64.2612.9 ,.0001
DLCO/VA (% predicted) 90.9614.7 90.7616.6 85.3615.9 72.7613.8*
` ,.0001
Dichotomous data are presented as number of individuals (% column totals) and continuous variables are presented as mean6SD for normally distributed variables.
*p,.05 vs no lung disease, following Bonferroni correction.
`p,.05 vs bronchiolitis, following Bonferroni correction.
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity, TLC, total lung capacity; RV, residual volume; DLCO, diffusing capacity of lung for
carbon monoxide or transfer factor; DLCO/VA, DLCO corrected for alveolar volume or transfer coefficient.
doi:10.1371/journal.pone.0109027.t004
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pathway is the additive effect of lung injury (from prior infection,
smoking, and illicit drug exposure) and the viral infection which
modifies the immune system responses, leading to chronic
inflammatory and senescent changes in major organs, such as
the lungs, liver and bone marrow. It is now well known that
despite long-term suppressive therapy with ART, chronic systemic
inflammation persists, which may amplify and accelerate the
pathogenesis of COPD in these individuals. Consistent with this
theory, we found that individuals with leukocytosis and elevated
CRP were more likely to demonstrate emphysema and bronchi-
olitis. Alternatively, some have shown that HIV infected individ-
uals experience premature senescence and multiple organ
pathologies. [22] They also demonstrate accelerated attrition of
telomeres in replicative cells such as certain leukocytes and
progenitor cells. [23,24] In experimental models, reduction in
telomere length has been shown to increase the risk of emphysema
in the presence of chronic cigarette smoke exposure. [25] It is also
notable that direct HIV variables such as current CD4 count and
plasma viral load had very little impact in predicting the
occurrence of emphysema or bronchiolitis most likely because
these patients were treated with ART and had a good clinical and
virologic response. These findings suggest that HIV related COPD
in the ART-era is driven predominantly by premature aging and
lifestyle factors (e.g. smoking, intravenous drug use).
Although there were commonalities in risk factor for emphy-
sema and bronchiolits, there were risk factors unique for these two
phenotypes. For example, increasing age was a risk factor for
emphysema but not bronchiolitis. These data are consistent with
Figure 3. The Synergistic Interaction of Emphysema with Bronchiolitis Scores on The Risk of Reduced Regular Physical Activity.
doi:10.1371/journal.pone.0109027.g003
Table 5. Risk Predictors for Bronchiolitis or Emphysema Detected on CT Scans.
Model Variables Crude OR (95% CI) ROC (95% CI) Multivariate OR (95% CI)* Incremental ROC (95%){ p`
1 Current Smoker 3.86 (3.08,4.85) 0.656 (0.631,
0.680)
3.48 (2.58, 4.71) 0.656 (0.631, 0.680) –
2 WBC (per 103 cells/mm3
increase)
1.23 (1.15, 1.32) 0.614 (0.579,
0.648)
1.13 (1.05, 1.22) 0.689 (0.656, 0.721) 0.0004
3 Intravenous Drug Use 2.65 (2.09, 3.37) 0.595 (0.573,
0.618)
2.14 (1.56, 2.94) 0.713 (0.681, 0.744) 0.0037
4 Age (per 10 year increase) 1.42 (1.24, 1.64) 0.577 (0.548,
0.606)
1.63 (1.35, 1.99) 0.730 (0.699, 0.760) 0.0360
5 BMI (per 5 kg/m2 decrease) 1.38 (1.20, 1.60) 0.568 (0.538,
0.598)
1.43 (1.18, 1.74) 0.733 (0.703, 0.764) 0.3145
6 Men 1.68 (1.33, 2.11) 0.552 (0.529,
0.576)
2.03 (1.46, 2.81) 0.743 (0.713, 0.773) 0.0679
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio; ROC, receiver operating characteristics; WBC, white blood cell;
*adjusted for all the variables listed in this table in a multivariate logistic regression model (see Methods for detail).
{Incremental ROC represents area under the curve obtained by adding the previous row variable to the current row variable in a multivariate logistic regression model
(see Methods for detail). For example, model 2 incremental ROC and p values are obtained by comparing a logic regression model that contains WBC and current
smoker variables to that which contains only current smoker variable (i.e. model 1).
`p value is obtained by comparing the incremental ROC value of the current row to the previous row ROC value.
doi:10.1371/journal.pone.0109027.t005
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the emerging concept that in most smokers, COPD changes first
start in the small airways with cigarette smoking and then progress
over time into the gas exchanging units, resulting in emphysema.
[26] In this regard, CT scanning that we did might not have been
sufficiently sensitive to detect early subtle changes in the small
airways. Another notable difference was the relationship of BMI to
the CT phenotypes. While there was a clear inverse relationship
between BMI and the risk of emphysema, its relation with
bronchiolitis was much weaker. The reasons for this are obscure
and will require additional investigations.
While CT scanning is extremely helpful for non-invasive
morphologic phenotyping and detection of early disease, it is
expensive and fraught with certain adverse effects and as such
should be used with caution. Our study indicates that knowledge
of certain risk factors may increase the chance of finding significant
abnormalities on CT scanning. Smoking status by itself has
relatively poor discrimination. The addition of peripheral leuko-
cyte count, a history of intravenous drug use and age to smoking
status, however, significantly increases discrimination from ‘‘poor’’
to the ‘‘fair’’ to ‘‘good’’ range. Further work will be needed to
optimize classifiers to accurately and cost-effectively identify HIV
infected patients who will benefit most from ‘‘screening’’ CT scans.
There were limitations to this study. First, we did not obtain
pulmonary function measurements in the entire cohort. As such,
the study may have lacked sufficient power to determine the
relationship of CT phenotypes to airflow limitation in HIV
infected patients. Second, the use of coronary calcium quantifi-
cation CT examinations in some subjects precluded full visuali-
zation of lung apices, diaphragm, and lung peripheries. However,
a previous study has shown an excellent (r = 0.93) correlation in
the extent of emphysema between cardiac and full lung scans,
proving some assurances. [27] It is also possible that the exclusion
of peripheral and apical areas of the lung may have led to the
underestimation of the radiographic burden of COPD in these
patients. Thus, our estimates of bronchiolitis and emphysema in
HIV infected individuals are likely conservative. Third, our study
was not designed to determine the long-term effects of COPD
phenotypes in HIV infected patients. Longer studies will be
needed to answer this critically important question. Fourth, as this
was a non-interventional observational study, we did not evaluate
the effects of pulmonary therapies in these patients. Finally, it
should be noted that the COPD phenotypic changes observed in
the present study are all based on CT imaging and not on
histology. Thus, it is possible that the pathogenesis and natural
history of ‘‘emphysema’’ and ‘‘bronchiolitis’’ in HIV may be
dissimilar to those related to smoking in the non-HIV patients.
Fourth, although none of the subjects in this study were suffering
an acute respiratory tract infection at the time of CT assessment,
we cannot be certain that bronchiolitis observed on CT scans
represents small airways disease of COPD. As our study did not
contain any expiratory scans, we could not assess gas trapping.
Future studies will be required to fully evaluate the causes of
bronchiolitis in HIV infected subjects.
Notwithstanding these and other limitations, the findings from
the present study have important clinical and public health
implications. First, the prevalence of bronchiolitis and emphysema
is huge in the HIV infected individuals (,50%) and manifests
much earlier than in the general population (40’s versus 60’s).
Spirometry, however, is insensitive in detecting significant
abnormalities in this patient population; CT scans are needed.
Second, the three leading risk factors for these CT phenotypes are:
smoking, peripheral leukocytosis and intravenous drug use in HIV
infected patients. In view of the high rates of smoking and
intravenous drug use among these patients, these data emphasize
the critical importance and pre-eminence of addiction treatment
in confronting the lung disease epidemic in these patients. These
data also highlight the likely importance of chronic systemic
inflammation in the pathogenesis of smoking-related lung disease
in HIV infected patients. Additional work will be needed to
confirm this hypothesis. Third, the use of simple clinical and
demographic data consisting of 4 risk factors (age, smoking status,
intravenous drug use and peripheral leukocyte count) may enable
more rational and cost-effective use of CT scanning for COPD
detection in HIV infected patients. CT scanning may also assist
clinicians in identifying source of unexplained dyspnea and
physical activity impairment in these patients. Additional work
will be needed to validate this notion.
In summary, this large study has demonstrated that morpho-
logically diagnosed emphysema in,35%, of HIV infected patients
who do not have a primary respiratory complaint. The COPD
epidemic will grow in strength and number as HIV infection
becomes a chronic illness. There is an urgent need to tackle the
enormous burden of lung disease in these patients through better
and more comprehensive management of their cigarette and illicit
drug addiction, improved education, and additional research on
mechanisms responsible for accelerated COPD in this group of
patients.
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